Literature DB >> 19369091

Aurora kinase inhibitors.

J J E M Kitzen1, M J A de Jonge, J Verweij.   

Abstract

Most human cancer cells are characterized by changes in the amount or organization of DNA resulting in chromosome instability and aneuploidy. Several mitotic kinases, Aurora kinases amongst others, regulate the progression of the cell through mitosis. So far three Aurora kinases have been identified in man: Aurora-A, Aurora-B and Aurora-C. Aurora kinases were recently identified as a potential target in anticancer therapy, and various Aurora-A and Aurora-B kinase inhibitors are in development. In this review we provide a brief insight into the mechanism of action as far as currently available. We review the available pre-clinical data, discuss the clinical phase I data and try to give a direction for future headings. 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19369091     DOI： 10.1016/j.critrevonc.2009.03.009

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  31 in total

Review 1.  Mechanisms of drug resistance in kinases.

Authors:  Rina Barouch-Bentov; Karsten Sauer
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.206

2.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

3.  Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.

Authors:  Sujatha Venkataraman; Irina Alimova; Tiffany Tello; Peter S Harris; Jeffrey A Knipstein; Andrew M Donson; Nicholas K Foreman; Arthur K Liu; Rajeev Vibhakar
Journal:  J Neurooncol       Date:  2012-01-15       Impact factor: 4.130

Review 4.  Recent advances in the development of Aurora kinases inhibitors in hematological malignancies.

Authors:  Iqra Choudary; Paul M Barr; Jonathan Friedberg
Journal:  Ther Adv Hematol       Date:  2015-12

Review 5.  Shared and separate functions of polo-like kinases and aurora kinases in cancer.

Authors:  Susanne M A Lens; Emile E Voest; René H Medema
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

6.  AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway.

Authors:  Jichang Wu; Liyun Yang; Yamin Shan; Changping Cai; Shili Wang; Hao Zhang
Journal:  Oncol Lett       Date:  2016-01-14       Impact factor: 2.967

7.  Phosphorylation regulates kinase and microtubule binding activities of the budding yeast chromosomal passenger complex in vitro.

Authors:  Anthony Cormier; David G Drubin; Georjana Barnes
Journal:  J Biol Chem       Date:  2013-06-27       Impact factor: 5.157

Review 8.  Development of anticancer drugs based on the hallmarks of tumor cells.

Authors:  Natalia Bailón-Moscoso; Juan Carlos Romero-Benavides; Patricia Ostrosky-Wegman
Journal:  Tumour Biol       Date:  2014-01-29

9.  Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.

Authors:  Kazuharu Kai; Kimie Kondo; Xiaoping Wang; Xuemei Xie; Mary K Pitner; Monica E Reyes; Angie M Torres-Adorno; Hiroko Masuda; Gabriel N Hortobagyi; Chandra Bartholomeusz; Hideyuki Saya; Debu Tripathy; Subrata Sen; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2015-10-06       Impact factor: 6.261

10.  Dysregulating IRES-dependent translation contributes to overexpression of oncogenic Aurora A Kinase.

Authors:  Tara Dobson; Juan Chen; Les A Krushel
Journal:  Mol Cancer Res       Date:  2013-05-09       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.